LOS ANGELES, March 10, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Linda Marbán, Ph.D., Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference on March 11, 2015 at 10:30 PT a.m. at The Ritz Carlton in Dana Point, California. Dr. Linda Marbán, will provide a company overview and update on its clinical development programs.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com.

CONTACT: Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance
         +1-310-358-3200
         abergmann@capricor.com
         
         Media Relations
         Russo Partners
         Christopher Hippolyte
         +1-646-942-5634
         chris.hippolyte@russopartnersllc.com
         
         Tony Russo, Ph.D.
         +1-212-845-4251
         tony.russo@russopartnersllc.com
         
         Investor Relations:
         Russo Partners
         Robert Flamm, Ph.D.
         +1-212-845-4226
         robert.flamm@russopartnersllc.com

Capricor Therapeutics logo